rabbit polyclonal anti-e2f5 antibody  (Santa Cruz Biotechnology)

Journal: BMC Cancer

Article Title: E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer

doi: 10.1186/1471-2407-10-64

Figure Lengend Snippet: Clinical characteristics and age distribution of study samples (serum samples) used for E2F5 and CA125 expression studies.

Article Snippet: Primary antibodies directed against the AREB6 (AVIVA Systems Biology, San Diego, California, USA), E2F5 (Acris GmbH, Hiddenhausen, Germany), PAX8 (Abcam Limited, Cambridge, UK), and ELF3 (Orbigen Inc, San Diego, CA) were chosen as the four TFs suggested by the bioinformatics analysis.

Techniques: Expressing

Journal: BMC Cancer

Article Title: E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer

doi: 10.1186/1471-2407-10-64

Figure Lengend Snippet: Summary of Immunohistochemistry results for E2F5 antibody tested on OEC

Article Snippet: Primary antibodies directed against the AREB6 (AVIVA Systems Biology, San Diego, California, USA), E2F5 (Acris GmbH, Hiddenhausen, Germany), PAX8 (Abcam Limited, Cambridge, UK), and ELF3 (Orbigen Inc, San Diego, CA) were chosen as the four TFs suggested by the bioinformatics analysis.

Techniques: Immunohistochemistry

Journal: BMC Cancer

Article Title: E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer

doi: 10.1186/1471-2407-10-64

Figure Lengend Snippet: Validation of potential target (AREB6, PAX8, ELF3) using western blots (A) and expression of E2F5 in serum from normal, benign and, malignant patient samples (B) . (A) Target validation using western blots of AREB6, PAX8, ELF3, in serum of healthy volunteers (N) (n = 2), patients with benign ovarian cysts (B1, B2) (n = 2), and patients with late- (L1, L2) (n = 2) and early-stage (E1-E3) (n = 3) serous adenocarcinoma. AREB6 was overexpressed in late stage disease, but was not discriminatory for early cancer. PAX8 and ELF3 were equally expressed in all serum samples. (B) Expression of E2F5 in serum from normal (n = 56), benign (n = 40) and, malignant (n = 48) serum obtained from patients with cancer of the ovary.

Article Snippet: Primary antibodies directed against the AREB6 (AVIVA Systems Biology, San Diego, California, USA), E2F5 (Acris GmbH, Hiddenhausen, Germany), PAX8 (Abcam Limited, Cambridge, UK), and ELF3 (Orbigen Inc, San Diego, CA) were chosen as the four TFs suggested by the bioinformatics analysis.

Techniques: Biomarker Discovery, Western Blot, Expressing

Journal: BMC Cancer

Article Title: E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer

doi: 10.1186/1471-2407-10-64

Figure Lengend Snippet: Details of E2F5/CA125 expression pattern on different subtypes of OEC performed using western blotting technique.

Article Snippet: Primary antibodies directed against the AREB6 (AVIVA Systems Biology, San Diego, California, USA), E2F5 (Acris GmbH, Hiddenhausen, Germany), PAX8 (Abcam Limited, Cambridge, UK), and ELF3 (Orbigen Inc, San Diego, CA) were chosen as the four TFs suggested by the bioinformatics analysis.

Techniques: Expressing, Western Blot

Journal: BMC Cancer

Article Title: E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer

doi: 10.1186/1471-2407-10-64

Figure Lengend Snippet: Diagnostic accuracy developed for ovarian cancer detection with 13 features using Kstar classification based on SMOTE algorithms.

Article Snippet: Primary antibodies directed against the AREB6 (AVIVA Systems Biology, San Diego, California, USA), E2F5 (Acris GmbH, Hiddenhausen, Germany), PAX8 (Abcam Limited, Cambridge, UK), and ELF3 (Orbigen Inc, San Diego, CA) were chosen as the four TFs suggested by the bioinformatics analysis.

Techniques: Diagnostic Assay